Display options
Cite
Quinn CH, Beierle AM, Beierle EA. Artificial Tumor Microenvironments in Neuroblastoma. Cancers (Basel). 2021;13(7)doi: 10.3390/cancers13071629.
Quinn, C. H., Beierle, A. M., & Beierle, E. A. (2021). Artificial Tumor Microenvironments in Neuroblastoma. Cancers, 13(7), . https://doi.org/10.3390/cancers13071629
Quinn, Colin H, et al. "Artificial Tumor Microenvironments in Neuroblastoma." Cancers vol. 13,7 (2021). doi: https://doi.org/10.3390/cancers13071629
Quinn CH, Beierle AM, Beierle EA. Artificial Tumor Microenvironments in Neuroblastoma. Cancers (Basel). 2021 Apr 01;13(7). doi: 10.3390/cancers13071629. PMID: 33915765; PMCID: PMC8037559.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Apr 01;13(7). doi: 10.3390/cancers13071629.

Artificial Tumor Microenvironments in Neuroblastoma.

Cancers

Colin H Quinn, Andee M Beierle, Elizabeth A Beierle

Affiliations

  1. Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35205, USA.
  2. Division of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35205, USA.

PMID: 33915765 PMCID: PMC8037559 DOI: 10.3390/cancers13071629

Abstract

In the quest to advance neuroblastoma therapeutics, there is a need to have a deeper understanding of the tumor microenvironment (TME). From extracellular matrix proteins to tumor associated macrophages, the TME is a robust and diverse network functioning in symbiosis with the solid tumor. Herein, we review the major components of the TME including the extracellular matrix, cytokines, immune cells, and vasculature that support a more aggressive neuroblastoma phenotype and encumber current therapeutic interventions. Contemporary treatments for neuroblastoma are the result of traditional two-dimensional culture studies and in vivo models that have been translated to clinical trials. These pre-clinical studies are costly, time consuming, and neglect the study of cofounding factors such as the contributions of the TME. Three-dimensional (3D) bioprinting has become a novel approach to studying adult cancers and is just now incorporating portions of the TME and advancing to study pediatric solid. We review the methods of 3D bioprinting, how researchers have included TME pieces into the prints, and highlight present studies using neuroblastoma. Ultimately, incorporating the elements of the TME that affect neuroblastoma responses to therapy will improve the development of innovative and novel treatments. The use of 3D bioprinting to achieve this aim will prove useful in developing optimal therapies for children with neuroblastoma.

Keywords: cancer associated fibroblasts; mesenchymal stromal cells; neuroblastoma; three-dimensional bioprinting; three-dimensional modeling; tumor associated macrophages; tumor microenvironment

References

  1. Science. 2014 May 23;344(6186):921-5 - PubMed
  2. Clin Cancer Res. 2013 Mar 1;19(5):1116-25 - PubMed
  3. Clin Cancer Res. 2007 Jul 1;13(13):3942-50 - PubMed
  4. Cancer Immunol Immunother. 2008 Apr;57(4):541-8 - PubMed
  5. EBioMedicine. 2018 Jun;32:84-92 - PubMed
  6. Clin Cancer Res. 2017 Feb 1;23(3):804-813 - PubMed
  7. Oncotarget. 2017 Sep 16;8(53):91516-91529 - PubMed
  8. Mol Cancer Ther. 2017 Nov;16(11):2516-2527 - PubMed
  9. Exp Cell Res. 2002 Apr 1;274(2):169-77 - PubMed
  10. Cancer Immunol Immunother. 2013 Oct;62(10):1637-48 - PubMed
  11. Molecules. 2016 Sep 08;21(9): - PubMed
  12. Cell Death Dis. 2014 Mar 20;5:e1135 - PubMed
  13. Biofabrication. 2016 Sep 23;8(3):032002 - PubMed
  14. Int J Cancer. 2020 Feb 15;146(4):1031-1041 - PubMed
  15. Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12877-82 - PubMed
  16. Int J Cancer. 2018 Sep 15;143(6):1483-1493 - PubMed
  17. Oncogene. 2020 Jan;39(1):64-78 - PubMed
  18. Br J Cancer. 1994 Apr;69(4):670-9 - PubMed
  19. J Biomech Eng. 2013 Sep;135(9):91011 - PubMed
  20. Oncol Rep. 2015 Apr;33(4):1837-43 - PubMed
  21. Recent Pat Drug Deliv Formul. 2012 Aug;6(2):149-55 - PubMed
  22. Cancer Lett. 2016 Feb 28;371(2):161-70 - PubMed
  23. PLoS One. 2012;7(10):e48654 - PubMed
  24. Nat Immun. 1998;16(5-6):263-74 - PubMed
  25. Front Biosci (Landmark Ed). 2010 Jan 01;15:166-79 - PubMed
  26. Cancer Immunol Res. 2019 Mar;7(3):363-375 - PubMed
  27. Int J Cancer. 2010 Mar 15;126(6):1339-52 - PubMed
  28. Cancer Res. 2013 Jul 1;73(13):3852-64 - PubMed
  29. J Extracell Vesicles. 2017 Jun 25;6(1):1332941 - PubMed
  30. Stem Cells Dev. 2021 Jan 15;30(2):59-78 - PubMed
  31. Oncotarget. 2014 Nov 30;5(22):11180-92 - PubMed
  32. Curr Opin Biotechnol. 2016 Aug;40:103-112 - PubMed
  33. Adv Pediatr. 2011;58(1):297-311 - PubMed
  34. Cancer Res. 2012 Aug 1;72(15):3735-43 - PubMed
  35. Cancer Res. 2003 Sep 15;63(18):5821-8 - PubMed
  36. J Oncol. 2018 Dec 16;2018:7946021 - PubMed
  37. Front Bioeng Biotechnol. 2020 Oct 08;8:924 - PubMed
  38. J Biol Chem. 2008 Jul 4;283(27):18573-81 - PubMed
  39. J Immunother. 2008 Nov-Dec;31(9):896-905 - PubMed
  40. Cancer Res. 2008 Jun 1;68(11):4311-20 - PubMed
  41. J Invest Dermatol. 2003 Feb;120(2):182-8 - PubMed
  42. Nat Biotechnol. 2014 Aug;32(8):773-85 - PubMed
  43. Int J Cancer. 2005 Mar 1;113(6):881-90 - PubMed
  44. Adv Healthc Mater. 2017 Aug;6(16): - PubMed
  45. Biofabrication. 2013 Dec;5(4):045010 - PubMed
  46. Cancer Res. 2012 May 1;72(9):2228-38 - PubMed
  47. Stem Cells. 2018 Jun;36(6):915-924 - PubMed
  48. Cells. 2020 Mar 11;9(3): - PubMed
  49. Cancer Lett. 1993 Sep 15;73(1):11-21 - PubMed
  50. Biotechnol J. 2011 Feb;6(2):204-212 - PubMed
  51. Am J Respir Cell Mol Biol. 2005 Dec;33(6):541-8 - PubMed
  52. Cancer Immunol Immunother. 1996 Mar;42(3):170-8 - PubMed
  53. Cancer Immunol Immunother. 2018 Apr;67(4):589-603 - PubMed
  54. J Clin Oncol. 1996 Feb;14(2):405-14 - PubMed
  55. Cancer Res. 2007 Mar 1;67(5):2331-8 - PubMed
  56. J Pers Med. 2021 Feb 13;11(2): - PubMed
  57. Cancer Discov. 2011 Jun;1(1):54-67 - PubMed
  58. Biomaterials. 2005 Jan;26(1):93-9 - PubMed
  59. Cancer Res. 2019 Oct 15;79(20):5382-5393 - PubMed
  60. Cancer Res. 2009 Jan 1;69(1):329-37 - PubMed
  61. BMC Biomed Eng. 2019 Dec 20;1:33 - PubMed
  62. Nat Protoc. 2009;4(3):309-24 - PubMed
  63. Cells. 2019 Aug 05;8(8): - PubMed
  64. Mol Ther. 2010 Nov;18(11):2006-17 - PubMed
  65. Front Immunol. 2020 Nov 26;11:584214 - PubMed
  66. Cancers (Basel). 2015 Dec 31;8(1): - PubMed
  67. Annu Rev Biomed Eng. 2013;15:177-200 - PubMed
  68. Cancer Lett. 2011 Dec 15;312(1):1-10 - PubMed
  69. World J Stem Cells. 2019 Dec 26;11(12):1065-1083 - PubMed
  70. Stem Cells Int. 2017;2017:4972078 - PubMed
  71. J Pathol. 2016 Oct;240(2):211-23 - PubMed
  72. Stem Cells Transl Med. 2012 Nov;1(11):792-802 - PubMed
  73. Cytotherapy. 2006;8(4):315-7 - PubMed
  74. Cell Rep. 2019 Jan 15;26(3):608-623.e6 - PubMed
  75. J Clin Invest. 2012 Jun;122(6):2221-33 - PubMed
  76. Cell Stem Cell. 2008 Sep 11;3(3):301-13 - PubMed
  77. Cancer Res. 2015 Apr 15;75(8):1592-602 - PubMed
  78. Adv Drug Deliv Rev. 2018 Jul;132:235-251 - PubMed
  79. Int J Cancer. 2006 Jan 15;118(2):310-6 - PubMed
  80. Front Immunol. 2017 Nov 03;8:1473 - PubMed
  81. Curr Opin Cell Biol. 2010 Oct;22(5):697-706 - PubMed
  82. Mater Today (Kidlington). 2015 Dec;18(10):539-553 - PubMed
  83. J Pediatr Surg. 1998 Aug;33(8):1272-8 - PubMed
  84. Curr Pharm Biotechnol. 2013;14(1):91-7 - PubMed
  85. Eur J Cancer. 1999 Mar;35(3):445-9 - PubMed
  86. Am J Pathol. 1987 Oct;129(1):74-85 - PubMed
  87. Viruses. 2018 Aug 26;10(9): - PubMed
  88. J Immunol. 2007 Sep 1;179(5):3332-41 - PubMed
  89. J Pediatr Surg. 1968 Feb;3(1):161-4 - PubMed
  90. J Clin Oncol. 2012 Oct 1;30(28):3525-32 - PubMed
  91. Cancers (Basel). 2020 Nov 02;12(11): - PubMed
  92. Pharmaceutics. 2020 Dec 06;12(12): - PubMed
  93. Cell Tissue Res. 2018 May;372(2):233-243 - PubMed
  94. Int J Cancer. 1998 Jul 29;77(3):449-54 - PubMed
  95. Nat Commun. 2021 Mar 12;12(1):1624 - PubMed
  96. Biomater Sci. 2018 May 1;6(5):915-946 - PubMed
  97. Cancer. 1999 Jul 15;86(2):364-72 - PubMed
  98. Adv Healthc Mater. 2015 Jun 24;4(9):1359-68 - PubMed
  99. Proteome Sci. 2014 Jul 11;12:39 - PubMed
  100. Cancer Res. 2017 Sep 15;77(18):5142-5157 - PubMed
  101. Cancer Res. 1998 Oct 15;58(20):4602-6 - PubMed
  102. J Pediatr Surg. 2003 Mar;38(3):301-7; discussion 301-7 - PubMed
  103. Clin Cancer Res. 2002 Sep;8(9):2912-23 - PubMed
  104. Front Immunol. 2018 Oct 16;9:2380 - PubMed
  105. Cancers (Basel). 2014 Jun 27;6(3):1363-81 - PubMed
  106. Biofabrication. 2019 Jan 24;11(2):025003 - PubMed
  107. Cancer Res. 2018 Mar 15;78(6):1471-1483 - PubMed
  108. Cancer Res. 2019 Mar 15;79(6):1151-1164 - PubMed
  109. Mol Cancer. 2017 Feb 1;16(1):31 - PubMed
  110. Trends Immunol. 2016 Mar;37(3):208-220 - PubMed
  111. Neoplasia. 2015 Jan;17(1):1-15 - PubMed
  112. Oncoimmunology. 2021 Jan 4;10(1):1838140 - PubMed
  113. Cancer Res. 2005 Jul 1;65(13):5506-11 - PubMed
  114. Clin Cancer Res. 2019 Aug 1;25(15):4761-4774 - PubMed
  115. Transl Oncol. 2021 Apr;14(4):101015 - PubMed
  116. Biomaterials. 2020 Feb;232:119744 - PubMed
  117. Clin Cancer Res. 2018 Oct 1;24(19):4820-4833 - PubMed
  118. Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6235-40 - PubMed
  119. Clin Cancer Res. 2016 Aug 1;22(15):3849-59 - PubMed
  120. Immunity. 2014 Jul 17;41(1):49-61 - PubMed
  121. Blood. 1998 Mar 1;91(5):1706-15 - PubMed
  122. Mod Pathol. 2009 Jul;22(7):950-8 - PubMed
  123. Nat Commun. 2018 Nov 8;9(1):4692 - PubMed
  124. Mol Ther. 2013 May;21(5):1034-43 - PubMed
  125. Nat Rev Cancer. 2012 Nov;12(11):767-75 - PubMed
  126. Cancer Res. 2006 Apr 1;66(7):3360-4 - PubMed
  127. Tissue Eng Part A. 2012 Jun;18(11-12):1304-12 - PubMed
  128. J Pediatr Surg. 2016 Dec;51(12):2068-2073 - PubMed
  129. Anticancer Res. 1994 Nov-Dec;14(6B):2453-6 - PubMed
  130. Cell Stem Cell. 2018 Jun 01;22(6):824-833 - PubMed
  131. Int J Clin Exp Pathol. 2015 Jan 01;8(1):504-10 - PubMed
  132. Acta Neuropathol. 1999 Mar;97(3):231-9 - PubMed
  133. Cancer Cell. 2020 Nov 9;38(5):716-733.e6 - PubMed
  134. Cancer Res. 2007 Feb 1;67(3):1030-7 - PubMed
  135. J Pathol. 2017 Feb;241(3):313-315 - PubMed
  136. Cytokine. 2006 Feb 21;33(4):188-98 - PubMed
  137. Biomaterials. 2012 Sep;33(26):6020-41 - PubMed
  138. Cell Res. 2020 Oct;30(10):833-853 - PubMed
  139. Eur J Cancer. 2021 Feb;144:123-150 - PubMed
  140. Mol Cancer Ther. 2008 Jul;7(7):1974-84 - PubMed
  141. J Clin Oncol. 2006 Dec 20;24(36):5725-34 - PubMed
  142. Nat Rev Cancer. 2003 Jun;3(6):422-33 - PubMed
  143. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14821-6 - PubMed

Publication Types

Grant support